Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis.

Antimicrobial Agents and Chemotherapy
D HenryJ J Collins

Abstract

Five hundred thirty-seven patients were enrolled in two independent, investigator-blinded, multicenter, randomized clinical trials comparing the clinical and bacteriologic efficacies and the safety of 5- or 10-day treatment with cefuroxime axetil with those of 10-day treatment with amoxicillin-clavulanate in the treatment of secondary bacterial infections of acute bronchitis. Patients received either 5 or 10 days of treatment (n = 177 in each group) with cefuroxime axetil at 250 mg twice daily or 10 days of treatment (n = 183) with amoxicillin-clavulanate at 500 mg three times daily. Patients in the cefuroxime axetil (5 days) group received placebo on days 6 to 10. Bacteriologic assessments were based on sputum specimen cultures obtained preceding and, when possible, following treatment. Organisms were isolated from the pretreatment sputum specimens of 242 of 537 (45%) patients, with the primary pathogens being Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Streptococcus pneumoniae, and Staphylococcus aureus (28, 25, 13, 9, and 8% of isolates, respectively). Pathogens were eradicated or presumed to be eradicated in 87% (52 of 60), 91% (53 of 58), and 86% (60 of 70) of bacteriologically evaluable pati...Continue Reading

References

Jan 1, 1991·Diagnostic Microbiology and Infectious Disease·G V Doern
Dec 1, 1990·The Journal of Antimicrobial Chemotherapy·H PortierF Guetat
Jul 1, 1990·Diagnostic Microbiology and Infectious Disease·G V Doern, T A Tubert
Aug 1, 1988·The Journal of Antimicrobial Chemotherapy·A M Emmerson
Jan 1, 1988·The Pediatric Infectious Disease Journal·W A HendrickseJ D Nelson
Feb 1, 1988·Archives of Internal Medicine·C J SchleupnerB Vogelman
Jan 1, 1988·Antimicrobial Agents and Chemotherapy·C C Knapp, J A Washington
Nov 1, 1987·Biopharmaceutics & Drug Disposition·A FinnJ Chubb
Mar 1, 1987·The Journal of Antimicrobial Chemotherapy·F P MaesenC Baur
Jan 1, 1984·Antimicrobial Agents and Chemotherapy·S M HardingJ Ayrton
Feb 1, 1984·The Journal of Antimicrobial Chemotherapy·P E Williams, S M Harding
Aug 1, 1993·Antimicrobial Agents and Chemotherapy·J A WashingtonC C Knapp

❮ Previous
Next ❯

Citations

Jul 31, 2008·Journal of Enzyme Inhibition and Medicinal Chemistry·Ozen OzensoyFeray Kockar
Jul 5, 2005·The American Journal of Medicine·Thomas G SlamaUNKNOWN Council for Appropriate and Rational Antibiotic Therapy (CARAT)
Jun 20, 2017·The Cochrane Database of Systematic Reviews·Susan M SmithLorne A Becker
Jun 17, 2020·Journal of Biomolecular Structure & Dynamics·Ashimiyu B DurojaiyeCan Wang
Apr 15, 2021·International Journal of Antimicrobial Agents·Felix CheyssonLaurence Watier

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.